Sex differences and the role of dopamine receptors in the reward-enhancing effects of nicotine and bupropion.
Nicotine and bupropion have been demonstrated to enhance the value of other reinforcers, and this may partially account for nicotine reward and dependence. Evidence suggests that the sexes differ in their sensitivity to the primary and secondary reinforcing effects of nicotine and nicotine-associated stimuli. Whether the sexes also differ in sensitivity to the reward-enhancing effects of nicotine (and bupropion) is yet unclear.



The present study evaluated potential sex differences in the enhancement effects of nicotine and bupropion using a reinforcer demand approach. Furthermore, we sought to investigate the role that D1- and D2-type dopamine receptors play in the reward-enhancing effects of nicotine and bupropion.



Demand for sensory reinforcement was assessed in male and female rats responding on a progression of fixed ratio schedules. The effects of nicotine and 10 or 20 mg/kg bupropion on reinforcer demand were assessed within subjects. Subsequently, the effects of SCH-23390 and eticlopride were assessed on the enhancing effects of nicotine and bupropion on progressive ratio responding.



Nicotine and bupropion enhanced demand metrics of reinforcement value in both sexes. Females were more sensitive to the enhancement effects of bupropion assessed by reinforcer demand and progressive ratio performance. D2-like dopamine receptor antagonism by eticlopride attenuated the enhancement effects of bupropion, but not of nicotine.



Nicotine and bupropion both enhance reinforcement value in both sexes, though females may be more sensitive to the reward-enhancing effects of bupropion. D2- and possibly D1-type receptors appear to be involved in the reward-enhancing effects of bupropion, but not necessarily nicotine.
Department of Psychology, University of Nebraska-Lincoln, 238 Burnett Hall, Lincoln, NE, 68588-0308, USA. s.taylor.barrett@gmail.com.
Scott T
ST
Barrett
Department of Psychology, University of Nebraska-Lincoln, 238 Burnett Hall, Lincoln, NE, 68588-0308, USA.
Trevor N
TN
Geary
Department of Psychology, University of Nebraska-Lincoln, 238 Burnett Hall, Lincoln, NE, 68588-0308, USA.
Amy N
AN
Steiner
Department of Psychology, University of Nebraska-Lincoln, 238 Burnett Hall, Lincoln, NE, 68588-0308, USA.
Rick A
RA
Bevins
D000818:Animals; D016642:Bupropion / Q000494:pharmacology*; D018492:Dopamine Antagonists / Q000494:pharmacology; D018765:Dopamine Uptake Inhibitors / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D005260:Female; D008297:Male; D009538:Nicotine / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D017447:Receptors, Dopamine D1 / Q000037:antagonists & inhibitors / Q000502:physiology*; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D012201:Reward; D012727:Sex Characteristics
D018492:Dopamine Antagonists; D018765:Dopamine Uptake Inhibitors; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D016642:Bupropion; D009538:Nicotine
Behavioral economics; Bupropion; Dopamine; Nicotine; Rats; Reinforcer demand; Reward enhancement; Sex differences
Clin Pharmacol Ther. 2006 May;79(5):480-8
16678549
J Exp Anal Behav. 2006 Jan;85(1):73-93
16602377
Curr Drug Abuse Rev. 2009 Sep;2(3):243-55
20443771
Front Biosci. 2008 Jan 01;13:505-16
17981564
Psychopharmacology (Berl). 2000 Dec;153(1):44-56
11255928
Synapse. 1990;5(2):157-64
2309159
Pharmacol Biochem Behav. 2007 Jan;86(1):32-6
17270256
Psychopharmacology (Berl). 2009 Dec;207(3):381-90
19760281
Psychopharmacology (Berl). 2013 Feb;225(3):707-18
22975726
Psychopharmacology (Berl). 2005 Jul;180(2):258-66
15682294
J Exp Anal Behav. 2014 Nov;102(3):353-62
25270581
Life Sci. 1997;61(12):PL 185-90
9315514
J Psychopharmacol. 2010 Jun;24(6):817-28
19304864
Behav Cogn Neurosci Rev. 2004 Sep;3(3):143-58
15653812
Neurosci Lett. 1997 Jul 18;230(2):140-2
9259484
Pharmacol Biochem Behav. 1999 Dec;64(4):803-12
10593204
Psychopharmacology (Berl). 2012 Oct;223(4):371-80
22592902
Biometrics. 1949 Jun;5(2):99-114
18151955
J Exp Anal Behav. 2012 Mar;97(2):183-202
22389525
Brain Res. 1993 Apr 30;610(1):127-34
8518920
Nicotine Tob Res. 2013 Oct;15(10):1696-704
23547276
Drug Des Devel Ther. 2014 Sep 18;8:1419-27
25258511
Psychopharmacology (Berl). 1994 Apr;114(3):477-85
7855206
J Comp Neurol. 2006 Jul 20;497(3):489-501
16736471
Neuropharmacology. 2014 Jan;76 Pt B:566-80
23684991
Brain Res. 1982 Sep 16;247(2):355-64
7127134
Behav Pharmacol. 2012 Dec;23(8):781-9
23080311
Behav Pharmacol. 2010 Mar;21(2):153-60
20168211
J Neural Transm. 1987;68(3-4):171-89
2881976
Neuroendocrinology. 1993 Jul;58(1):16-22
8264850
Psychopharmacology (Berl). 2007 Nov;194(4):463-73
17616849
Drug Des Devel Ther. 2013 Sep 27;7:1053-62
24101861
Handb Exp Pharmacol. 2009;(192):29-60
19184645
J Neurosci. 1997 Nov 1;17(21):8580-7
9334429
Psychopharmacology (Berl). 2002 Sep;163(2):194-201
12202966
Alcohol Clin Exp Res. 1997 Sep;21(6):1083-91
9309321
Pharmacol Biochem Behav. 2013 Dec;114-115:9-15
24422211
Front Psychiatry. 2015 Feb 18;6:24
25762943
Neurosci Biobehav Rev. 2004 Oct;28(6):533-46
15527861
Neurosci Res. 1985 Apr;2(4):211-20
4022457
Horm Behav. 2010 Jun;58(1):44-56
19818789
Psychopharmacology (Berl). 2002 Nov;164(2):121-37
12404074
Pharmacol Biochem Behav. 1994 Jan;47(1):107-12
8115411
Neuropharmacology. 2012 Jun;62(7):2267-77
22342988
Pharmacol Biochem Behav. 2014 Mar;118:1-9
24388843
Prim Care Companion J Clin Psychiatry. 2004;6(4):159-166
15361919
Eur J Pharmacol. 1985 May 8;111(2):191-9
4018125
Brain Res. 1984 Jan 2;290(1):67-75
6692140
Brain Res Bull. 1986 May;16(5):681-8
3742250
Psychol Rev. 2008 Jan;115(1):186-98
18211190
J Comp Neurol. 2016 Jun 1;524(8):1699-711
26272220
Brain Res. 1983 Nov 14;278(1-2):262-5
6640314
Neuropharmacology. 2013 Dec;75:138-44
23916479
Drug Alcohol Depend. 2014 Feb 1;135:22-8
24332790
Annu Rev Pharmacol Toxicol. 2009;49:57-71
18834313